James Ryan - BioNTech Chief Board
| 0A3M Stock | USD 97.18 2.78 2.78% |
Executive
James Ryan is Chief Board of BioNTech SE
| Age | 50 |
| Address | An der Goldgrube 12, Mainz, Germany, 55131 |
| Phone | 49 6131 9084 0 |
| Web | https://www.biontech.de |
James Ryan Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Ryan against BioNTech stock is an integral part of due diligence when investing in BioNTech. James Ryan insider activity provides valuable insight into whether BioNTech is net buyers or sellers over its current business cycle. Note, BioNTech insiders must abide by specific rules, including filing SEC forms every time they buy or sell BioNTech'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Ryan over six months ago Disposition of 130000 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Payment of 15970 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Payment of 10936 shares by James Ryan of Gray Television subject to Rule 16b-3 | ||
James Ryan over a year ago Acquisition by James Ryan of 1883 shares of Ballys Corp subject to Rule 16b-3 |
BioNTech Management Efficiency
The company has return on total asset (ROA) of 0.1692 % which means that it generated a profit of $0.1692 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2382 %, meaning that it generated $0.2382 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. At this time, BioNTech's Net Tangible Assets are quite stable compared to the past year. Other Assets is expected to rise to about 300.9 M this year, although the value of Total Current Assets will most likely fall to about 10.8 B.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Adam Ray | Charter Communications Cl | 48 | |
| Jose Prieto | Cellnex Telecom SA | N/A | |
| Kyle Malady | Verizon Communications | 57 | |
| Robert Penfold | Playtech Plc | N/A | |
| Patrick Graf | St Galler Kantonalbank | 52 | |
| Gvantsa Murghvliani | TBC Bank Group | N/A | |
| Leigh Rimmer | Lendinvest PLC | N/A | |
| Simon Fuchs | St Galler Kantonalbank | N/A | |
| MaryLee Stillwell | Verizon Communications | 50 | |
| Lauren Iannarone | Playtech Plc | N/A | |
| Jeff Murphy | Charter Communications Cl | N/A | |
| Jessica Fischer | Charter Communications Cl | 38 | |
| Jacob Perlman | Charter Communications Cl | 47 | |
| Gianluca Landolina | Cellnex Telecom SA | N/A | |
| Samantha Hammock | Verizon Communications | 46 | |
| Sowmyanarayan Sampath | Verizon Communications | 47 | |
| Sandeep Gandhi | Playtech Plc | N/A | |
| Stefan Anninger | Charter Communications Cl | N/A | |
| Bidzina Matsaberidze | TBC Bank Group | N/A | |
| Ian Ince | Playtech Plc | N/A | |
| Sharon Peters | Charter Communications Cl | 49 | |
Management Performance
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.17 |
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jens Holstein, CFO Board | ||
| Oliver Hennig, VP Operations | ||
| Sylke Maas, VP Strategy | ||
| James Ryan, Chief Board | ||
| Michael Boehler, MD Communications | ||
| Ryan Richardson, MD Officer | ||
| Sierk Poetting, COO MD | ||
| Pr MD, CoFounder Board | ||
| Ozlem MD, Chief CoFounder | ||
| Sean Marett, Chief Officer |
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | ||||
| Return On Asset | 0.17 | ||||
| Profit Margin | 0.48 % | ||||
| Operating Margin | 0.64 % | ||||
| Current Valuation | 5.74 B | ||||
| Shares Outstanding | 239.77 M | ||||
| Shares Owned By Insiders | 65.11 % | ||||
| Shares Owned By Institutions | 17.59 % | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 2.91 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.